London (PRWEB UK) 13 April 2015
With one in five people having allergies, there is a growing demand for new developments and greater understanding of where the field of allergy therapeutics is going.
Set to take place on 8th & 9th July in London, Allergies 2015 will gather a global audience of leading scientists and specialists in the healthcare industry as they explore current pathways to the developments of novel therapeutics. The conference will focus on developments of novel vaccines and adjuvants for immunotherapy, along with a strong focus on allergy clinical trials and pharmacovigilance to gain a solid understanding of the current requirements and obligations in the development of immunotherapy products. The programme will highlight increasing patient compliance and increasing quality of life for patients that are being treated on a day to day basis through new mechanisms of delivery. There will also an emphasis on personalised medicines for the treatment of specific phenotypes rather than taking the one fits all strategy and new pathways for pioneering targeting strategies to be developed.
Keynote address will include Quintiles’ senior medical director. European Head Allergy, Respiratory, Infectious Diseases and Vaccines, Juan Gispert, will discuss the increasing probability of success in allergy clinical trials looking at recruitment of patients, compliance in long term trials and clinical trials in paediatric population. MedImmune’s Research Scientist, Ian Strickland will speak on Advances in the field of Atopic Dermatitis and Tim Higenbottam, R&D Director from Allergy Therapeutics will discuss formulation and delivery of state of the art allergy therapeutics.
The 2-day agenda will feature over 17 case study driven presentations, industry speakers representing MedImmune, Circassia, HAL Allergies, DBV Technologies, Quintiles plus many more and over 3 hours of networking with industry professionals who are leading the way in Allergies.
The conference will feature 2 workshops on improving probability of success in allergy clinical trials led by Quintiles’s Dr Juan Gispert & Vivienne McDonald and UCL’s Dr Virginina Calder will present a workshop on: Tear Biomarkers for ocular Allergy
Inflamax Research Inc will be sponsoring and speaking at the conference.
A brochure with a full list of speakers and presentations is available to download online. For further information or to book a place, visit Marriott Regents Park Hotel, London, UK
Delegate enquiries contact: Andrew Gibbons on +44 (0)20 7827 6156 or email agibbons(at)smi-online.co(dot)uk
2nd Annual Allergies Conference
8th & 9th July 2015,
Marriott Regents Park Hotel, London, UK
--------------- END ---------------
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk.